Sabag Mark sold 46,000 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD at $41.93 for −$1.93M on Nov 5, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
See "Remarks"
See "Remarks"
Filed Nov 6, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$1,928,729.40Shares × reported price
Shares traded
46,000Ordinary Shares
Price per share
$41.93Reported price. Read footnotes for ranges.
% of reported position traded
36.29%This security and ownership context
Holdings after
80,760Direct
Trade date
Nov 5, 2026Sell
Filed
Nov 6, 2026, 4:03 PM ET1-day reporting delay
Accession
0001193125-26-451814Code S · Transaction 394583
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 126,760 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 5, 2026Option exercise46,000$34.90$1,605,400Trade 394582
Nov 5, 2026Option exercise46,000$0.00$0Trade 394584
3 transaction rows in this filing. Joint filers share the same rows.

TEVA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TEVA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −8.2%1w ago −4.7%1d ago −4.7%
Returns since7d +4.4%30d90d180d1y

Footnotes in full

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.81 to $42.08, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. F2: Stock options were granted on February 14, 2017, with 30,236 vested on each of February 14, 2018, February 14, 2019 and February 14, 2020, and 30,238 vested on February 14, 2021.